UnitedHealthcare Community Plan PDL Modifications
|
|
- Ilene Carr
- 5 years ago
- Views:
Transcription
1 Lialda Mesalamine Apriso Mesalamine treatment of ulcerative colitis. treatment of ulcerative colitis. Afinitor Disperz Everolimus treatment of subependymal giant cell astrocytoma (SEGA) with tuberous sclerosis complect (TSC). Prior authorization required. Available through Bosulif Bosutinib of chronic phase, accelerated phase, or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy. Prior Iclusig Ponatinib of chronic phase, accelerated phase, or blast phase chronic myelogenous leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy and for the treatment of Philadelphia chromosome-positive acute lymphocytic leukemia (ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. Prior authorization required. Available through Cometriq Cabozantinib of progressive, metastatic medullary thyroid cancer. Prior authorization required. Available through Stivarga Cystaran solution 0.44% Gattex Regorafenib Cysteamine Teduglutide of metastatic colorectal cancer in patients who have previously received fluoropyrimidine, oxaliplatin, and irinotecan based chemotherapy; an anti-vegf therapy; and an anti-egfr therapy if KRAS wild type. Also for the treatment of locally advanced, unresectable or metastatic gastrointestinal stromal tumors (GIST) in patients who have previously received imatinib and sunitinib. Prior of corneal cysteine crystal accumulation in patients with cystinosis. Prior authorization required. Available through specialty pharmacy. of short bowel syndrome in patients who are dependent on parenteral support. Prior * Only Generics are covered Page 1 of 5
2 Juxtapid Lomitapide of homozygous familial hypercholesterolemia (HoFH). Prior authorization required. Available through Marinol* Aubagio Gilenya Dronabinol* Teriflunomide Fingolimod of chemotherapy-induced nausea/vomiting (CINV) that is refractory to conventional antiemetic agents and for use as an appetite stimulant in patients with anorexia due to AIDS. Prior authorization required. of relapsing forms of multiple sclerosis. Prior of relapsing forms of multiple sclerosis. Prior Eliquis Norditropin Apixaban Somatropin Ritalin LA* Methylphenidate ER* Eli Lilly Insulin Vials: Humalog Insulin Lispro Humilin R Insulin Regluar Humulin N Insulin Isophane Humulin 70/30 Insulin Isophane/Regular Humalog Mix 75/25 Insulin Lispro Prot/Lispro Humalog Mix 50/50 Insulin Lispro Prot/Lispro Added as an alternative agent for stroke prophylaxis and systemic embolism prophylaxis in patients with nonvalvular atrial fibrillation. Prior authorization required. treatment of growth failure due to growth hormone deficiency. Prior authorization required. Available through specialty pharmacy. treatment of attention-deficit hyperactivity disorder (ADHD). Added as alternative insulin formulations for the treatment of type 1 and type 2 diabetes mellitus. AccuNeb 0.63 mg/3 ml and 1.25 mg/3 ml* Albuterol 0.63 mg/3 ml and 1.25 mg/3 ml* Added as alternative dosing formulations for the treatment of acute bronchospasm (eg, asthma) and bronchospasm prophylaxis. Age edit applies for members 8 years of age or older. Prior authorization is required for members 8 years of age or older. Omnitrope Cimzia Hecoria* Combivent Respimat Somatropin Certolizumab pegol Tacrolimus Ipratropium/albuterol inhaler Alternative formulations are available on the PDL including Tev-Tropin and Norditropin. Current users will not be grandfathered. including Enbrel and Humira. Current users will not be grandfathered. Added as alternative formulation for the treatment of heart, kidney, and liver transplant rejection prophylaxis. Added as alternative formulation to for the treatment of chronic obstructive pulmonary disease (COPD). * Only Generics are covered Page 2 of 5
3 Detrol* Tolterodine Sanctura* Duoneb* Plan B One Step* Trospium Ipratropium/albuterol solution for inhalation Levonorgestrel 1.5 mg tab of an overactive bladder with symptoms of urinary frequency, urinary urgency, or urgerelated urinary incontinence. Step therapy of an overactive bladder with symptoms of urinary frequency, urinary urgency, or urgerelated urinary incontinence. Step therapy Added as alternative formulation to for the treatment of chronic obstructive pulmonary disease (COPD). Added as an alternative dosing formulation for postcoital contraception. Added as alternative blood glucose testing strips. Lifescan (OneTouch, Basic, Profile, SureStep, Ultra ) Test Strips Effexor XR capsules* Venlafaxine ER capsules Modification Step therapy removed. Peg-Intron Peginterferon alfa-2b Bayer (BREEZE 2, CONTOUR and ASCENSIA ) Test Strips 3/1/2013 4/1/2013 Isentress Chewable Raltegravir chewable tablet 3/1/2013 4/1/2013 Lyrica Solution Pregabalin oral solution 3/1/2013 4/1/2013 Xtandi Enzalutamide including Pegasys (peginterferon alfa-2a). Current users will be able to complete their current regimens. Alternative diabetic blood glucose testing strips are available on the PDL including Roche (Accu- Chek Aviva, Aviva Plus, Active, Comfort Curve, Compact, SmartView) and Lifescan (OneTouch Basic, Profile, SureStep, Ultra, Verio ) test strips. Current users will not be grandfathered treatment of HIV infection in combination with other antiretroviral agents. Added as alternative dosing formulation to for the treatment of diabetic neuropathy, fibromyalgia, partial seizures, postherpetic neuralgia, and pain associated with spinal cord injury. Prior authorization required. metastatic castration-resistant prostate cancer in patients who have received prior chemotherapy containing docetaxel. Prior 3/1/2013 4/1/2013 Stribild Cobicistat/elvitegravir/ emtricitabine/tenofovir of HIV infection in antiretroviral naïve adults. 3/1/2013 4/1/2013 Entocort Budesonide 3/1/2013 4/1/2013 Rectiv Nitroglycerin rectal ointment 3/1/2013 4/1/2013 Adderall* Amphet/d-amphet salts Modification 3/1/2013 4/1/2013 Adderall XR Amphet/d-amphet salts XR Modification 3/1/2013 4/1/2013 Strattera Atomoxetine Modification 3/1/2013 4/1/2013 Dexedrine* Dextroamphetamine Modification 3/1/2013 4/1/2013 Dextrostat* Dextroamphetamine Modification 3/1/2013 4/1/2013 Dexedrine Spansule* Dextroamphetamine ER Modification 3/1/2013 4/1/2013 Intuniv Guanfacine Modification 3/1/2013 4/1/2013 Ritalin* Methylphenidate Modification of Crohn s disease. Prior authorization required. of pain associated with anal fissures. Prior authorization required. Maximum age edit changed to 18 years of age. Prior authorization is required for patients 18 years of age and older. Age edit modification only applies to new starts. Current users will be grandfathered. *Only Generics are covered 3/1/2013 4/1/2013 Concerta* Methylphenidate ER Modification 3/1/2013 4/1/2013 Metadate ER* Methylphenidate SR Modification 3/1/2013 4/1/2013 Ritalin SR* Methylphenidate SR Modification 3/1/2013 4/1/2013 Vyvanse Lisdexamfetamine Modification * Only Generics are covered Page 3 of 5
4 3/1/2013 4/1/2013 Adcirca Tadalafil 3/1/2013 4/1/2013 Pristiq Desvenlafaxine Avonex Pen Interferon beta-1a Korlym Pulmicort Inhaler Symbicort Cimzia Penlac Solution 8%* Desenex Powder 2%* Aclovate Cream and Ointment 0.05%* Temovate Gel and Cream 0.5%* Derma-Smooth Oil/FS* Locoid Solution, Cream, and Ointment 0.1%* Dermatop Cream and Ointment 0.1%* Bleph 10 Ophthalmic Ointment* Optipranolol Ophthalmic Sol 0.3%* Dexasol Ophthalmic Sol 0.1%* FML Forte Opthalmic Sus 0.25%* Vasoclear Ophthalmic Sol 0.02%* Clear Eyes Redness Relief* Mifepristone Budesonide inhalation Budesonide/formoterol Certolizumab pegol Ciclopirox Miconazole topical powder Alclometasone topical cream Clobetasol topical gel and cream Fluocinolone acetonide topical oil Hydrocortisone butyrate topical solution, cream, Prednicarbate topical cream Sulfacetamide Sodium 10% Metipranolol Ophthalmic Dexamethasone sodium phosphate Fluorometholone Naphazoline HCl Naphazoline-Glycerin including sildenafil citrate 20 mg tablet, Letairis, and Tracleer. Current users will be grandfathered. including venlafaxine, venlafaxine ER capsules, fluoxetine, sertraline, paroxetine, and citalopram. Current users will be grandfathered. treatment of multiple sclerosis. Prior Added as alternative agent to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Prior Added as an alternative agent for the maintenance treatment of asthma. Added as an alternative agent for the maintenance treatment of asthma. Step therapy rheumatoid arthritis and Crohn s disease. Prior Added as an alternative agent for treatment of mild to moderate onychomycosis of fingernails and toenails. treatment of tinea pedis, tinea corporis, tinea cruris, and tinea versicolor. of atopic dermatitis. of conjunctivitis, corneal ulcer and other superficial infections. Added as an alternative agent for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. treatment of allergic conjunctivitis and allergic marginal corneal ulcer. treatment of allergic conjunctivitis, ocular burns or trauma due to corneal injury, thermal or penetration trauma, giant papillary conjunctivitis (GPC), keratitis, postoperative ocular inflammation, vernal keratoconjunctivitis, and chronic anterior uveitis. * Only Generics are covered Page 4 of 5
5 Vasoclear A Ophthalmic Naphazoline/Zinc sulfate Sol* Visine-AC Ophthalmic Sol* Tetrahydrozoline/Zinc sulfate Muro 128 Ophthalmic Sol 5%* Victrelis Cyclocort 0.1% Cream* Lokara Lotion 0.5%* Topicort Cream and Gel 0.05%* Topicort Cream and Ointment 0.25%* Apexicon Cream and Ointment 0.05%* Westcort Ointment 0.2%* Sodium chloride hypertonic Boceprevir Amcinonide topical cream Desonide topical lotion Desoximetasone topical cream and gel Desoximetasone topical cream Diflorasone topical cream and ointment Hydrocortisone valerate topical ointment Added as an alternative agent for the relief of redness of the eye due to minor irritations or relief of burning and irritation due to dryness of the eye or discomfort due to minor irritations. relief of corneal edema. An alternative agent is available on the PDL including Incivek. Current users will be grandfathered. including desonide ointment and cream, alclometasone, fluocinolone, hydrocortisone, and triamcinolone. including betamethasone, fluocinolone, fluticasone cream, hydrocortisone acetate, hydrocortisone butyrate, mometasone, and triamcinolone. * Only Generics are covered Page 5 of 5
UnitedHealthcare Community Plan PDL Modifications
Lialda Mesalamine Apriso Mesalamine Afinitor Disperz Everolimus treatment of ulcerative colitis. treatment of ulcerative colitis. treatment of subependymal giant cell astrocytoma (SEGA) with tuberous sclerosis
More informationUnitedHealthcare Community Plan PDL Modifications
12/1/2013 1/1/2014 Mekinist Trametinib 12/1/2013 1/1/2014 Tafinlar Dabrafenib 12/1/2013 1/1/2014 Tudorza Pressair Aclidinium inhalation 12/1/2013 1/1/2014 Cystagon Cysteamine bitartrate 12/1/2013 1/1/2014
More informationUnitedHealthcare Community Plan PDL Modifications. Added as an alternative agent for the 9/1/ /1/2012
Avonex Pen Interferon beta-1a Added as alternative dosing formulation for the treatment of multiple sclerosis. Prior Korlym Mifepristone Added as alternative agent to control hyperglycemia secondary to
More informationStep Therapy Medications
Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on
More information2015 Step Therapy Prior Authorization Medical Necessity Guidelines
Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154
More informationDrug Formulary Update, January 2013
Drug Formulary Update, January 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota
More information2018 Step Therapy (ST) Criteria
2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationDrug Formulary Update, April 2013
Drug Formulary Update, April 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota
More informationAlameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions
Alameda Alliance for Health FORMULARY UPDATE Effective: October 27, 2017. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee
More informationComparison of representative topical corticosteroid preparations (classified according to the US system)
Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More informationPrescription benefit updates Large group
Prescription benefit updates Large group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe effective medication treatments. The program also helps you save money
More informationQuarterly pharmacy formulary change notice
Provider Bulletin June 2017 The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. These changes were reviewed and approved at the first quarter Pharmacy and Therapeutics
More informationRelative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
More informationAfinitor. Afinitor and Afinitor Disperz (everolimus) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 9 Last Review Date: June 22, 2018 Afinitor Description Afinitor and
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE January 22, 2013 SUBJECT EFFECTIVE DATE January 15, 2013 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Drug List (PDL) Update January 15, 2013 Pharmacy Services Vincent D. Gordon, Deputy
More informationTABLE OF CONTENTS (Click on a link below to view the section.)
Follow the links below to access the complete formularies for Plans: Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)
More informationAetna Better Health of Illinois Medicaid Formulary Updates
October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017
More informationBLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES
BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.
More informationJuly 2017 P&T Updates
July 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth Alternatives ALUNBRIG 3 2 DUPIXENT Pharmacy 3 2 6 tablets per day, 30 day One-week auth for QL of 3 syringes per
More informationAlprazolam 0.25mg, 0.5mg, 1mg tablets
Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service
More informationMichigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan
Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: Introductions Approval of Minutes of July 8, 2014 Meeting P & T Business Review
More informationTABLE OF CONTENTS (Click on a link below to view the section.)
Follow the links below to access the complete formularies for Plans: Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationADHD Medications Table
Stimulants are the first line treatment of choice for ADHD followed by Non-Stimulants, then off-label medications. We are providing this list of medications so that you can be familiar with the common
More informationStep Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)
CareAdvantage CMC 2018 Formulary Supplement II (List of Covered Drugs) Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) Formulary ID: 00018157 Formulary Version:11 19 CMS Approved: 08/21/2018
More informationThe safety and effectiveness of Dupixent in pediatric patients have not been established (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent
More informationNB Drug Plans Formulary Update
Bulletin # 963 December 15, 2017 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective December 15, 2017. Included in this bulletin: Special Authorization Benefit
More informationEffective for all members on August 1, 2017
August 2017 Pharmacy Formulary Change Notice BlueChoice HealthPlan Medicaid is here to help you stay on top of your health care. We want to tell you about some upcoming changes to your Preferred Drug List
More informationBLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES
BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.
More informationTennCare Program TN MAC Price Change List As of: 03/30/2017
1 TN List Run : 03/30/17 Old PRAZOSIN HCL 5 MG CAPSULE ORAL 03/29/2017 1.11209 1.12560 ( 1.2) CAPTOPRIL 12.5 MG TABLET ORAL 07/07/2015 1.07191 1.10416 ( 2.9) ISOSORBIDE DINITRATE 5 MG TABLET ORAL 03/29/2017
More informationAdvanced Control Formulary Change Summary Report Effective
This report highlights all changes (additions, deletions, and removals) to the CVS Caremark Advanced Control Formulary ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Cystagon (cysteamine bitartrate)
More informationPharmacy Policy Updates-Medicare Advantage
Pharmacy Policy Updates-Medicare Advantage The following recommendations included on this update have been approved by the Pharmacy and Therapeutics Committee. Please note: For Medicare Advantage plans
More informationCENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description
CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY Coverage Guideline Policy & Procedure HIM.PA.32 Long acting stimulants (Adderall XR, Dexedrine, Metadate CD, Ritalin
More informationLABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION
LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION Added Prior Authorization 7/1/17 CORLANOR 5 MG TABLET Added Prior Authorization 7/1/17 CORLANOR 7.5 MG TABLET Added Prior Authorization 7/1/17
More informationNew Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.
Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.
More informationTABLE OF CONTENTS (Click on a link below to view the section.)
Follow the links below to access the complete formularies for Plans: Buckeye Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral
More informationPrescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals)
This report highlights all changes (additions, deletions and removals) to the CVS Caremark Prescribing Guide Standard Control. ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Estring (estradiol)
More informationStivarga. Stivarga (regorafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.26 Subject: Stivarga Page: 1 of 5 Last Review Date: September 15, 2017 Stivarga Description Stivarga
More information2017 Formulary Changes Year to Date
2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or
More informationRAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)
INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193
More informationPharmacy and Therapeutics (P&T) Committee Meeting February 16, :00 PM 8:00 PM MINUTES
P&T Committee Members Matthew Flynn, MD Randy Grigg, MD Kenneth Kohagen, MD David Konanc, MD Sheila Marshall, DO Jennifer Smith, PharmD Michael Spiritos, MD State Health Plan (SHP) Staff David Boerner,
More informationCRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.
ADHD STIMULANTS ATOMOXETINE HCL, DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE
More informationDRUG SCHEDULES REGULATION CHANGES JUNE 2018
DRUG SCHEDULES REGULATION CHANGES JUNE 2018 The following amendments to the Schedules to the Drug Schedules Regulation made under the Pharmacy Operations and Drug Scheduling Act came into effect on June
More informationNB Drug Plans Formulary Update
Bulletin # 914 October 14, 2015 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective October 14, 2015. Included in this bulletin: Special Authorization Benefit
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationPharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines
More informationPEI Drug Programs. Issue February 20, 2009
PEI Drug Programs Formulary Update Issue 09-01 February 20, 2009 New medications for the treatment of cancer, chronic obstructive pulmonary disease (COPD), osteoporosis, and HIV/AIDS have been approved
More informationOregon Health Plan prescription benefit updates
Oregon Health Plan prescription benefit updates EOCCO s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps you save
More informationComparison of representative topical corticosteroid preparations (classified according to the US system)
Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),
More informationDrug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative
More informationUPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting
UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationPharmacologic Treatment of Atopic Dermatitis
J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc
More informationGA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy
Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine
More informationAD/HD is a mental disorder, and it often lasts from
short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.
More informationAttention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
More informationIMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members
IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance
More informationUPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting
UPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting
More informationStep Therapy Criteria 2019
Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD
More informationAcyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria
Medications that require Step Therapy (ST) require trial and failure of preferred formulary agents prior to their authorization. If the prerequisite medications have been filled within the specified time
More informationQuarterly pharmacy formulary change notice
MEDICAID PROVIDER BULLETIN October 2018 The formulary changes listed in the table below were reviewed and approved at the second-quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More informationALLERGIC RHINITIS-NASAL
ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step
More informationBlueLink TPA FlexRx Updates
BlueLink TPA FlexRx Updates April 2018 TRADE NAME (generic name) or generic name abacavir sulfate soln 20 mg/ml (base equiv) Generic Addition, generic for ZIAGEN alclometasone dipropionate cream 0.05%
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at our second quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
More informationStep Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 05/01/2018 Updated 4/2018 H0302_2_2014 CMS Accepted 05/05/2014 1 BETA-BLOCKERS BYSTOLIC 10 MG
More informationMercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria
ALBENDAZOLE Mercy Care ALBENZA TABLET 200 MG ORAL Refer to PA Guideline for approval criteria 1 BRIMONIDINE-TIMOLOL COMBIGAN SOLUTION 0.2-0.5 % OPHTHALMIC Requires use of separate ingredients for at least
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationDEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code
More informationKentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations
Kentucky Department for Medicaid Services Pharmacy and March 15, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee
More informationDrugs That Require Prior Authorization (PA) Before Being Approved for Coverage
Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage You will need authorization by your UA Medicare Part D Prescription Drug Plan before filling prescriptions for the drugs shown
More informationStimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information
Adderall and Adderall-XR (amphetamine mixtures) Concerta (methylphenidate, controlled Dexedrine, Dexedrine Spansules (dextroamphetamine) Focalin (dexmethylphenidate) Metadate, Metadate-ER, and Metadate-CD
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationMercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir
Acyclovir Ointment Mercy Care Plan acyclovir ointment 5 % external Requires use of oral Acyclovir 1 Adcirca ADCIRCA TABLET 20 MG ORAL Requires use of Sildenafil 2 Albenza ALBENZA TABLET 200 MG ORAL Requires
More informationTexas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)
Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so
More informationAlameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions
Alameda Alliance for Health FORMULARY UPDATE Effective: February 15, 2018. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationPharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS
Workforce Safety & Insurance Revised Document Date: 07/23/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More information2018 Step Therapy (ST) Criteria
2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationPharmacy Benefit Determination Policy
Policy Subject: Atopic Dermatitis Agents Policy Number: SHS PBD18 Category: Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS PPO ASO s:
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1067-7 Program Prior Authorization/Notification Medication Nexavar (sorafenib tosylate) P&T Approval Date 8/2008, 6/2009, 6/2010,
More informationAdded, Removed or Changed. Date of Change. No Change
One mission: you s September 7, 2017 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your
More informationQuarterly pharmacy formulary change notice
Provider Bulletin October 2018 Quarterly pharmacy formulary change notice The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. The changes listed in the table
More informationStep Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More information35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: ADHD Medications P&T DATE 12/13/2017 CLASS: Psychiatric Disorders REVIEW HISTORY 12/16, 9/15, 5/12, 5/10, LOB: MCL (MONTH/YEAR)
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
More informationTABLE OF CONTENTS (Click on a link below to view the section.)
Follow the links below to access the complete formularies for Plans: Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral
More informationConversion from focalin xr to vyvanse
Conversion from focalin xr to vyvanse The Borg System is 100 % Conversion from focalin xr to vyvanse Sep 3, 2007. The importance of the 'conversion' dosing listed above relates to those people who may
More information